NCT01299116 - Long-Acting Reversible Contraception | Biotech Hunter

Enrollment

916

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2016

Conditions

Contraception

Interventions

DRUG

DMPA

Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.

DRUG

oral contraceptives

Oral contraceptives (any variety of formulations are permitted)

DRUG

Implanon®

Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)

DRUG

ParaGard®

Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)

DRUG

Mirena®

Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)

Trial Locations (1)

27514

Planned Parenthood Central North Carolina, Chapel Hill

All Listed Sponsors

lead

FHI 360

OTHER